Synthetic Biologics Inc. announced Klaus Gottlieb, MD, FACG, has joined the Company as Vice President, Clinical & Regulatory Affairs, effective June 22, 2015. Dr. Gottlieb's appointment expands the clinical and regulatory leadership team as the Company moves into Phase 2 clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs. He will report to Joseph Sliman, MD, MPH, Synthetic Biologics' Senior Vice President, Clinical & Regulatory Affairs. Dr. Gottlieb joins Synthetic Biologics after serving as Senior Medical Director-Therapeutic Strategy Lead Gastroenterology of Quintiles.

At Quintiles, Dr. Gottlieb served as Global Medical Advisor for three separate large Phase 3 inflammatory bowel disease (IBD) trials.